Theodore W. Laetsch, MD is a faculty member in the Department of Pediatrics at the University of Texas Southwestern Medical Center in Dallas, TX. He also leads the Experimental Therapeutics Program (ETP) in the Gill Center for Cancer and Blood Disorders at Children’s Health in Dallas, TX. Dr. Laetsch received a BS in Agricultural and Biosystems Engineering from the University of Arizona and then a MD from the University of California, San Francisco. Dr. Laetsch completed his residency at the University of Colorado/Children’s Hospital Colorado, where he also served as chief resident. He completed his fellowship training and an instructorship at the Children's Hospital of Philadelphia (CHOP), where he conducted translational laboratory research focused on mechanisms to restore apoptotic signaling in neuroblastoma in the laboratory of Dr. Michael Hogarty. In 2013, he joined the faculty at UT Southwestern. Dr. Laetsch conducts both clinical and laboratory-based research testing potential novel therapeutics in high-risk pediatric solid tumors with a goal of “bridging the gap” between laboratory research and early phase clinical trials. In the laboratory, he has focused on signaling pathway inhibitors and novel drug delivery mechanisms in sarcomas, and the use of beta-lapachone in ATRTs. As the leader of the ETP program, Dr. Laetsch serves as the PI of several phase 1 and phase 2 studies of new agents for children with relapsed or refractory cancer and serves as the institutional TACL PI. Dr. Laetsch has a strong interest in the use of tumor molecular profiling to guide therapy. In addition to these research activities, Dr. Laetsch continues to see children with cancer in the clinic at Children’s Medical Center.
- Medical School
- University of California, San Francisco (2005)
- University of Colorado - Children's Hospital Colorado - Pediatric Internship/Residency (2009), Pediatrics
- Children's Hospital of Philadelphia - Pediatric Hema/Onco Fellowship (2012), Pediatric Hematology/oncology
- Novel Therapeutics for Childhood Cancer
- Tumor Genomic Profiling
- Larotrectinib for the treatment of TRK fusion solid tumors.
- Laetsch TW, Hawkins DS Expert Rev Anticancer Ther 2018 Oct 1-10
- Integrative Bayesian Analysis Identifies Rhabdomyosarcoma Disease Genes.
- Xu L, Zheng Y, Liu J, Rakheja D, Singleterry S, Laetsch TW, Shern JF, Khan J, Triche TJ, Hawkins DS, Amatruda JF, Skapek SX Cell Rep 2018 Jul 24 1 238-251
- Undifferentiated sarcomas in children harbor clinically-relevant oncogenic fusions and gene copy-number alterations: A report from the Children's Oncology Group.
- Laetsch TW, Roy A, Xu L, Black JO, Coffin CM, Chi YY, Tian J, Spunt SL, Hawkins DS, Bridge JA, Parsons DW, Skapek SX Clin. Cancer Res. 2018 Apr
- Pan-Trk Immunohistochemistry Identifies NTRK rearrangements in Pediatric Mesenchymal Tumors.
- Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, Rajaram V, Laetsch TW, Davis JL Am. J. Surg. Pathol. 2018 Apr
- False-positive results following lentiviral-based tisagenlecleucel therapy with select HIV-1 NAT methods.
- Laetsch TW, Maude SL, Milone MC, Davis KL, Krueger J, Cardenas AM, Eldjerou LK, Keir CH, Wood PA, Grupp SA Blood 2018 Apr
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
- Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS Lancet Oncol. 2018 Mar
- EGF Receptor and mTORC1 are novel therapeutic targets in nonseminomatous germ cell tumors.
- Chen KS, Fustino NJ, Shukla AA, Stroup EK, Budhipramono A, Ateek C, Stuart SH, Yamaguchi K, Kapur P, Frazier AL, Lum L, Looijenga LHJ, Laetsch TW, Rakheja D, Amatruda JF Mol. Cancer Ther. 2018 Feb
- Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
- Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM N. Engl. J. Med. 2018 02 378 8 731-739
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
- Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA N. Engl. J. Med. 2018 02 378 5 439-448
- Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing.
- Huynh V, Laetsch TW, Schore RJ, Gaynon P, O'Brien MM Pediatr Hematol Oncol 2017 Nov 1-14
Honors & Awards
- Rising Star Award
UT Southwestern Leaders in Clinical Excellence (2018)
- NICHD Child Health Research Career Development Award (K12)
- Joseph W. St. Geme, Jr., M.D. Award for Outstanding Research as a Resident
- Gold Headed Cane Society Member
- Alpha Omega Alpha Member
- American Association of Cancer Research (2010)
- American Society of Clinical Oncology (2010)
- American Society of Pediatric Hematology/Oncology (2009)
- Children's Oncology Group (2009)